Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cytek Biosciences director Imper Vera increased her equity stake through compensation-related awards. On June 10, 2026, she exercised 43,973 Restricted Stock Units that had fully vested the same day, receiving an equal number of common shares and bringing her direct common stock holdings to 59,679 shares.
She also received grants of 18,261 director stock options with a $4.05 exercise price expiring on June 10, 2036, and 33,333 new Restricted Stock Units. Both the new option and RSU awards vest 100% on the earlier of June 10, 2027 or Cytek’s 2027 annual meeting of stockholders, if that meeting is held in June 2027. No open-market buys or sales were reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
43,973 shares exercised/converted
Mixed
4 txns
Insider
Imper Vera
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 33,333 | $0.00 | -- |
| Grant/Award | Director Stock Option (right to buy) | 18,261 | $0.00 | -- |
| Exercise | Restricted Stock Units | 43,973 | $0.00 | -- |
| Exercise | Common Stock | 43,973 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 33,333 shares (Direct, null);
Director Stock Option (right to buy) — 18,261 shares (Direct, null);
Common Stock — 59,679 shares (Direct, null)
Footnotes (1)
- Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). 100% of the shares subject to the RSU Award vested on June 10, 2026.
Key Figures
RSUs exercised into common stock: 43,973 shares
Common shares held after transactions: 59,679 shares
Director stock options granted: 18,261 options at $4.05
+3 more
6 metrics
RSUs exercised into common stock
43,973 shares
Restricted Stock Units exercised on June 10, 2026
Common shares held after transactions
59,679 shares
Direct Cytek Biosciences common stock holdings post-transaction
Director stock options granted
18,261 options at $4.05
Grant on June 10, 2026; expires June 10, 2036
New RSUs granted
33,333 units
Grant on June 10, 2026, vesting by June 10, 2027 or 2027 annual meeting
Vesting date of prior RSU award
June 10, 2026
100% of shares under the earlier RSU Award vested on this date
Vesting schedule for new awards
By June 10, 2027
New RSUs and option vest earlier of June 10, 2027 or 2027 annual meeting in June
Key Terms
Restricted Stock Unit, Director Stock Option (right to buy), vesting, annual meeting of stockholders, +1 more
5 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Director Stock Option (right to buy) financial
"Director Stock Option (right to buy) with an exercise price of 4.0500"
vesting financial
"100% of the shares subject to the RSU Award vested on June 10, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders"
exercise price financial
"Director Stock Option ... with a conversion or exercise price of 4.0500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What insider transactions did Imper Vera report for Cytek Biosciences (CTKB)?
Imper Vera reported compensation-related equity activity, not open-market trading. She exercised 43,973 vested Restricted Stock Units into common shares and received new grants of 18,261 director stock options and 33,333 Restricted Stock Units, all dated June 10, 2026, increasing her overall equity exposure.
What stock options were granted to Imper Vera by Cytek Biosciences (CTKB)?
Imper Vera received 18,261 director stock options with a $4.05 exercise price. These options are exercisable into Cytek Biosciences common stock and expire on June 10, 2036. The entire option award vests on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting, if held in June.
What new Restricted Stock Units did Imper Vera receive from Cytek Biosciences (CTKB)?
She was granted 33,333 new Restricted Stock Units, each representing a contingent right to one Cytek Biosciences common share. All units vest 100% on the earlier of June 10, 2027 or the 2027 annual meeting of stockholders, provided that meeting occurs in June 2027, aligning vesting with board service.
When did Imper Vera’s previously granted Cytek Biosciences RSUs vest?
Footnotes state that 100% of the shares subject to the earlier Restricted Stock Unit award vested on June 10, 2026. That same day, Imper Vera exercised 43,973 vested units into an equal number of Cytek Biosciences common shares, increasing her direct stock holdings accordingly.